Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MHLW Warns About Side Effects Before Interferon Treatment Starts

This article was originally published in PharmAsia News

Executive Summary

Starting in April in Japan, hepatitis B and C patients who use the antiviral interferon will be able to receive aid from the government. The program will require patients to pay monthly ¥10,000 to ¥50,000 based on individual income levels and the rest will be covered by the government. As a result, the Ministry of Health, Labor and Welfare estimates that an additional 100,000 patients every year will take interferon treatment. So that patients are aware of potential side effects, MHLW put out a warning March 27. Currently, interferon's label includes warnings about interstitial pneumonitis and suicidal tendencies. MHLW also warns about depression and bleeding due to thrombocytopenia. (Click here for more-Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068036

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel